Therefore, our novel findings suggest that Cur and PTX combination may be a promising strategy for ovarian cancer treatment, and targeting miR-9-5p/BRCA1 axis may help to improve therapeutic outcomes. This evidence concerns the gene BRCA1 and ovarian carcinoma.